662 Encinitas Blvd. Suite 248, Encinitas, CA 92024
We are specialized in developing small molecule therapeutics for cancer.
The lead drug in our pipeline is a dual inhibitor small molecule called AP-001 that prevents growth and metastasis of the cancer cells.
AP-001 is an anti-cancer drug developed by Avenzoar.
AP-001 is a small molecule dual inhibitor that targets two pro-cancer pathways at the same time. Pre-clinical results show strong prevention of pancreatic cancer growth and metastasis with no significant toxicity.
AP-001 kills the cancer cells isolated from the blood of pancreatic cancer patients. These are the cells in the process of spreading to other organs and they are resistant to most chemotherapies.
AP-001 will be tested in pancreatic cancer patients in the first half of 2018. Lung and liver cancer patients will be considered for clinical trials as the pre-clinical results show that AP-001 affects lung and liver cancer cells.